PBM Industry Pushes Back Against Pharma Lobbyists

Amid growing scrutiny of pharmacy benefit managers (PBMs) at the public and congressional level, a PBM industry group has launched an ad campaign pointing the blame back at pharma for high drug prices. The group argues that the pharmaceutical industry has spent millions of dollars on advertising and lobbying that places the onus of high drug prices on PBM practices while side skirting their own responsibility for setting list prices.

According to Beth Snyder Bulik, “Earlier this month, the drug industry’s trade association PhRMA launched its own campaign at PBMs, claiming the middlemen decide which medicines patients can get. That effort was the third in a series that portrays PBMs as an uncaring man in a suit who sides with insurance companies.”

To read more, click here.

(Source: Endpoints News, May 31^st, 2023)